Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Eli Lilly & Co. (NYSE:LLY)

Analysis of Long-term (Investment) Activity Ratios

Beginner level

Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.

Long-term Activity Ratios (Summary)

Eli Lilly & Co., long-term (investment) activity ratios

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Net fixed asset turnover 2.83 2.75 2.59 2.57 2.48
Net fixed asset turnover (including operating lease, right-of-use asset) 2.66 2.75 2.59 2.57 2.48
Total asset turnover 0.57 0.56 0.51 0.55 0.56
Equity turnover 8.56 2.50 1.97 1.52 1.37

Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Eli Lilly & Co.’s net fixed asset turnover ratio improved from 2017 to 2018 and from 2018 to 2019.
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Eli Lilly & Co.’s net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from 2017 to 2018 but then slightly deteriorated from 2018 to 2019 not reaching 2017 level.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Eli Lilly & Co.’s total asset turnover ratio improved from 2017 to 2018 and from 2018 to 2019.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Eli Lilly & Co.’s equity turnover ratio improved from 2017 to 2018 and from 2018 to 2019.

Net Fixed Asset Turnover

Eli Lilly & Co., net fixed asset turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Revenue 22,319,500  24,555,700  22,871,300  21,222,100  19,958,700 
Property and equipment, net 7,872,900  8,919,500  8,826,500  8,252,600  8,053,500 
Long-term Activity Ratio
Net fixed asset turnover1 2.83 2.75 2.59 2.57 2.48
Benchmarks
Net Fixed Asset Turnover, Competitors2
Abbott Laboratories 3.97 4.04 3.60 3.66 3.56
AbbVie Inc. 11.23 11.36 10.07 9.85 8.91
Amgen Inc. 4.51 4.54 4.37 4.41 4.27
Bristol-Myers Squibb Co. 4.18 4.49 4.15 3.90 3.75
Gilead Sciences Inc. 4.91 5.41 7.79 10.45 14.13
Illumina Inc. 3.99 3.10 2.96 3.36 6.48
Johnson & Johnson 4.65 4.79 4.50 4.52 4.41
Merck & Co. Inc. 3.11 3.18 3.23 3.31 3.16
Pfizer Inc. 3.71 4.01 3.79 3.97 3.55
Regeneron Pharmaceuticals Inc. 2.72 2.61 2.49 2.33 2.57
Vertex Pharmaceuticals Inc. 5.59 3.75 3.15 2.44 1.48
Zoetis Inc. 3.23 3.51 3.70 3.54 3.65
Net Fixed Asset Turnover, Sector
Pharmaceuticals & Biotechnology 4.11 4.22 4.08 4.20 4.10
Net Fixed Asset Turnover, Industry
Health Care 6.02 6.11 5.89 6.07 5.70

Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).

1 2019 Calculation
Net fixed asset turnover = Revenue ÷ Property and equipment, net
= 22,319,500 ÷ 7,872,900 = 2.83

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Eli Lilly & Co.’s net fixed asset turnover ratio improved from 2017 to 2018 and from 2018 to 2019.

Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Eli Lilly & Co., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Revenue 22,319,500  24,555,700  22,871,300  21,222,100  19,958,700 
 
Property and equipment, net 7,872,900  8,919,500  8,826,500  8,252,600  8,053,500 
Operating lease assets 532,100  —  —  —  — 
Property and equipment, net (including operating lease, right-of-use asset) 8,405,000  8,919,500  8,826,500  8,252,600  8,053,500 
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1 2.66 2.75 2.59 2.57 2.48
Benchmarks
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2
Abbott Laboratories 3.56 4.04 3.60 3.66 3.56
AbbVie Inc. 10.06 11.36 10.07 9.85 8.91
Amgen Inc. 4.11 4.54 4.37 4.41 4.27
Bristol-Myers Squibb Co. 3.76 4.49 4.15 3.90 3.75
Gilead Sciences Inc. 4.28 5.41 7.79 10.45 14.13
Illumina Inc. 2.45 3.10 2.96 3.36 6.48
Johnson & Johnson 4.41 4.79 4.50 4.52 4.41
Merck & Co. Inc. 2.90 3.18 3.23 3.31 3.16
Pfizer Inc. 3.39 4.01 3.79 3.97 3.55
Regeneron Pharmaceuticals Inc. 2.70 2.61 2.49 2.33 2.57
Vertex Pharmaceuticals Inc. 5.00 3.75 3.15 2.44 1.48
Zoetis Inc. 2.94 3.51 3.70 3.54 3.65
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector
Pharmaceuticals & Biotechnology 3.77 4.22 4.08 4.20 4.10
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry
Health Care 5.38 6.11 5.89 6.07 5.70

Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).

1 2019 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenue ÷ Property and equipment, net (including operating lease, right-of-use asset)
= 22,319,500 ÷ 8,405,000 = 2.66

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Eli Lilly & Co.’s net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from 2017 to 2018 but then slightly deteriorated from 2018 to 2019 not reaching 2017 level.

Total Asset Turnover

Eli Lilly & Co., total asset turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Revenue 22,319,500  24,555,700  22,871,300  21,222,100  19,958,700 
Total assets 39,286,100  43,908,400  44,981,000  38,805,900  35,568,900 
Long-term Activity Ratio
Total asset turnover1 0.57 0.56 0.51 0.55 0.56
Benchmarks
Total Asset Turnover, Competitors2
Abbott Laboratories 0.47 0.46 0.36 0.40 0.49
AbbVie Inc. 0.37 0.55 0.40 0.39 0.43
Amgen Inc. 0.37 0.34 0.27 0.28 0.29
Bristol-Myers Squibb Co. 0.20 0.64 0.62 0.58 0.52
Gilead Sciences Inc. 0.36 0.34 0.37 0.53 0.62
Illumina Inc. 0.48 0.48 0.52 0.56 0.60
Johnson & Johnson 0.52 0.53 0.49 0.51 0.53
Merck & Co. Inc. 0.55 0.51 0.46 0.42 0.39
Pfizer Inc. 0.31 0.34 0.31 0.31 0.29
Regeneron Pharmaceuticals Inc. 0.53 0.57 0.67 0.70 0.73
Vertex Pharmaceuticals Inc. 0.50 0.49 0.70 0.59 0.41
Zoetis Inc. 0.54 0.54 0.62 0.64 0.60
Total Asset Turnover, Sector
Pharmaceuticals & Biotechnology 0.40 0.46 0.41 0.42 0.43
Total Asset Turnover, Industry
Health Care 0.51 0.57 0.51 0.53 0.51

Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).

1 2019 Calculation
Total asset turnover = Revenue ÷ Total assets
= 22,319,500 ÷ 39,286,100 = 0.57

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Eli Lilly & Co.’s total asset turnover ratio improved from 2017 to 2018 and from 2018 to 2019.

Equity Turnover

Eli Lilly & Co., equity turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Revenue 22,319,500  24,555,700  22,871,300  21,222,100  19,958,700 
Total Eli Lilly and Company shareholders’ equity 2,606,900  9,828,700  11,592,200  14,007,700  14,571,300 
Long-term Activity Ratio
Equity turnover1 8.56 2.50 1.97 1.52 1.37
Benchmarks
Equity Turnover, Competitors2
Abbott Laboratories 1.03 1.00 0.89 1.02 0.96
AbbVie Inc. — — 5.54 5.53 5.79
Amgen Inc. 2.30 1.80 0.86 0.73 0.75
Bristol-Myers Squibb Co. 0.51 1.61 1.77 1.20 1.16
Gilead Sciences Inc. 0.98 1.01 1.26 1.59 1.73
Illumina Inc. 0.77 0.89 1.00 1.09 1.20
Johnson & Johnson 1.38 1.37 1.27 1.02 0.98
Merck & Co. Inc. 1.81 1.58 1.17 0.99 0.88
Pfizer Inc. 0.82 0.85 0.74 0.89 0.75
Regeneron Pharmaceuticals Inc. 0.71 0.77 0.96 1.09 1.12
Vertex Pharmaceuticals Inc. 0.68 0.69 1.23 1.47 1.10
Zoetis Inc. 2.31 2.67 3.00 3.29 4.46
Equity Turnover, Sector
Pharmaceuticals & Biotechnology 1.28 1.41 1.17 1.12 1.05
Equity Turnover, Industry
Health Care 1.42 1.52 1.36 1.34 1.22

Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).

1 2019 Calculation
Equity turnover = Revenue ÷ Total Eli Lilly and Company shareholders’ equity
= 22,319,500 ÷ 2,606,900 = 8.56

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Eli Lilly & Co.’s equity turnover ratio improved from 2017 to 2018 and from 2018 to 2019.